Trizivir, Combination Drug for HIV

Although the disease of HIV/AIDS yet found the most potent drug to treat it, but the medical community recommends Trizivir to suppress the development of the HIV virus in the body.

Trizivir is believed to treat human immunodeficiency virus infection (HIV).

Trizivir is an oral drug combinations containing abacavir (Ziagen), lamivudine (Epivir) and AZT (Retrovir).


The three types of drugs that are three anti-HIV drugs with different mechanisms of action are also different. Anti-HIV drugs are often used in combination to enhance the suppression of HIV and to reduce the likelihood of HIV viral resistance may develop to any single drug.

Surviving are three types of drugs into one pill, can reduce the amount of drug that must be consumed by someone. Making it easier for patients to keep the rules of taking drugs for therapy.

Giving one Trizivir tablet with 300 mg of abacavir, 150 mg lamivudine, and zidovudine 300 mg together. However, Trizivir does not reduce HIV transmission among individuals, and does not cure HIV or AIDS.

Trizivir was approved by the Food and Drugs Administration (FDA) in November 2000. This drug can only be obtained by prescription.

Trizivir composition in a single tablet, among others, contains 300 mg of abacavir, 150 mg lamivudine, 300 mg zidovudine.

Trizivir is used alone or in combination with other anti-HIV drugs for the treatment of HIV infection the recommended dose for adults is one tablet two times daily.

The side effects of Trizivir as drug components, ie abacavir, lamivudine, and zidovudine. The most common side effects, namely nausea, diarrhea, vomiting, weight loss and difficulty sleeping.

Serious hypersensitivity reactions associated with abacavir, which is one component of Trizivir, also sometimes fatal and can involve multiple organs. Symptoms of hypersensitivity reactions may include fever, rash, nausea, vomiting, diarrhea, sore throat, abdominal pain, fatigue, pain and shortness of breath.

Patients should stop taking Trizivir if you have a hypersensitivity reaction. Patients who carry a specific genetic marker called HLA-B 5701 are at high risk for experiencing a hypersensitivity reaction to abacavir. Screening for HLA-B 5701 allele is recommended prior to initiating therapy with abacavir.

Posted in: Disease and Cure